Polyrizon

Polyrizon Financial Leverage

The Financial Leverage (Equity Multiplier) of Polyrizon (PLRZ) as of Oct 21, 2026 is 1.02. In the previous year, Financial Leverage (Equity Multiplier) was 1.05 — a change of -2.69% (lower).

Financial Leverage

1.02

YoY

-2.69%

Last updated:

Financial Leverage (Equity Multiplier) of Polyrizon is 2025 1.02 . Financial Leverage (Equity Multiplier) of Polyrizon was 2024 1.05 . It decreases by -2.69% lower compared to the previous year.

The Polyrizon Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2020
1.50 USD
Jan 1, 2021
-229.00 USD
Jan 1, 2022
-0.84 USD
Jan 1, 2023
9.81 USD
Jan 1, 2024
1.05 USD
Jan 1, 2025
1.02 USD
The Polyrizon Financial Leverage history
YEARFinancial LeverageYoY
1.02-2.69%
1.05-89.30%
9.81-1,271.09%
-0.84-99.63%
-229.00-15,366.67%
1.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Financial Leverage (Equity Multiplier) of Polyrizon is 1.02 in 2025.

Financial Leverage (Equity Multiplier) of Polyrizon changed from 1.05 to 1.02, representing a -2.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Polyrizon since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Polyrizon with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Polyrizon

All Key Metrics — Polyrizon